# reload+after+2024-01-21 17:44:45.279675
address1§409 Illinois Street
city§San Francisco
state§CA
zip§94158
country§United States
phone§415 978 1200
fax§415 978 1902
website§https://www.fibrogen.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
fullTimeEmployees§592
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Thane  Wettig', 'age': 58, 'title': 'CEO & Director', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 807345, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Juan  Graham', 'age': 46, 'title': 'Senior VP & CFO', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 991757, 'exercisedValue': 0, 'unexercisedValue': 221113}, {'maxAge': 1, 'name': 'Ms. Christine L. Chung', 'age': 55, 'title': 'Senior Vice President of China Operations', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 1274738, 'exercisedValue': 0, 'unexercisedValue': 104427}, {'maxAge': 1, 'name': 'Dr. Barry A. Berkowitz Ph.D.', 'title': 'Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. John J. Hunter Ph.D.', 'age': 60, 'title': 'Chief Scientific Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'David  DeLucia', 'title': 'Vice President of Corporate FP&A and Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael D. Lowenstein J.D., Ph.D.', 'title': 'Chief Legal Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tricia  Stewart', 'title': 'Chief People Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kirk A. Christoffersen MBA', 'age': 54, 'title': 'Chief Business Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Rahul Rajan Kaushik Ph.D.', 'title': 'Senior Vice President of Pharmaceutical Development, Technical Operations & Manufacturing', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§10
boardRisk§2
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.746
priceToSalesTrailing12Months§0.47589806
currency§USD
dateShortInterest§1702598400
forwardEps§-1.36
exchange§NMS
quoteType§EQUITY
shortName§FibroGen, Inc
longName§FibroGen, Inc.
firstTradeDateEpochUtc§1415975400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§36a357a0-624b-3e04-a14d-dbb6b1255b8f
gmtOffSetMilliseconds§-18000000
targetHighPrice§2.0
targetLowPrice§0.5
targetMeanPrice§1.25
targetMedianPrice§1.25
recommendationMean§3.5
recommendationKey§hold
numberOfAnalystOpinions§2
quickRatio§1.352
grossMargins§-0.73822
ebitdaMargins§-1.5859
trailingPegRatio§None
